Switch theme
Sign up to access all valuation multiples
Qingdao Baheal Medical Inc is engaged in providing comprehensive marketing services for pharmaceutical product manufacturers.
2005
n/a
LTM Revenue $1.2B
LTM EBITDA $150M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Qingdao Baheal Medical has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $150M.
In the most recent fiscal year, Qingdao Baheal Medical achieved revenue of $1.1B and an EBITDA of $157M.
Qingdao Baheal Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Qingdao Baheal Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $441M | XXX | $399M | XXX | XXX | XXX |
| Gross Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBITDA | $150M | XXX | $157M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $135M | XXX | $141M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $99.5M | XXX | $96.0M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $103M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Qingdao Baheal Medical's stock price is CNY 18 (or $2).
Qingdao Baheal Medical has current market cap of CNY 9.4B (or $1.3B), and EV of CNY 10.1B (or $1.4B).
See Qingdao Baheal Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.3B | XXX | XXX | XXX | XXX | $0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Qingdao Baheal Medical has market cap of $1.3B and EV of $1.4B.
Qingdao Baheal Medical's trades at 1.2x EV/Revenue multiple, and 8.9x EV/EBITDA.
Equity research analysts estimate Qingdao Baheal Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Qingdao Baheal Medical has a P/E ratio of 13.1x.
See valuation multiples for Qingdao Baheal Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 9.3x | XXX | 8.9x | XXX | XXX | XXX |
| EV/EBIT | 10.4x | XXX | 10.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.1x | XXX | 13.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 19.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialQingdao Baheal Medical's last 12 month revenue growth is 16%
Qingdao Baheal Medical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Qingdao Baheal Medical's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Qingdao Baheal Medical's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Qingdao Baheal Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Qingdao Baheal Medical acquired XXX companies to date.
Last acquisition by Qingdao Baheal Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Qingdao Baheal Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Qingdao Baheal Medical founded? | Qingdao Baheal Medical was founded in 2005. |
| Where is Qingdao Baheal Medical headquartered? | Qingdao Baheal Medical is headquartered in China. |
| Is Qingdao Baheal Medical publicy listed? | Yes, Qingdao Baheal Medical is a public company listed on SHE. |
| What is the stock symbol of Qingdao Baheal Medical? | Qingdao Baheal Medical trades under 301015 ticker. |
| When did Qingdao Baheal Medical go public? | Qingdao Baheal Medical went public in 2021. |
| Who are competitors of Qingdao Baheal Medical? | Similar companies to Qingdao Baheal Medical include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
| What is the current market cap of Qingdao Baheal Medical? | Qingdao Baheal Medical's current market cap is $1.3B |
| What is the current revenue of Qingdao Baheal Medical? | Qingdao Baheal Medical's last 12 months revenue is $1.2B. |
| What is the current revenue growth of Qingdao Baheal Medical? | Qingdao Baheal Medical revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Qingdao Baheal Medical? | Current revenue multiple of Qingdao Baheal Medical is 1.2x. |
| Is Qingdao Baheal Medical profitable? | Yes, Qingdao Baheal Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Qingdao Baheal Medical? | Qingdao Baheal Medical's last 12 months EBITDA is $150M. |
| What is Qingdao Baheal Medical's EBITDA margin? | Qingdao Baheal Medical's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Qingdao Baheal Medical? | Current EBITDA multiple of Qingdao Baheal Medical is 9.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
